| Identification | Back Directory | [Name]
Ly93 | [CAS]
1883528-69-5 | [Synonyms]
Ly93
SMS2-IN-Ly93
2-[(2-ethylphenyl)methoxy]-N-(pyridin-3-yl)benzamide | [Molecular Formula]
C21H20N2O2 | [MDL Number]
MFCD32067900 | [MOL File]
1883528-69-5.mol | [Molecular Weight]
332.4 |
| Chemical Properties | Back Directory | [Boiling point ]
450.6±35.0 °C(Predicted) | [density ]
1.191±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (752.11 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.67±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1]. | [Biological Activity]
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1].
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1]. | [in vivo]
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].
Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1]. | Animal Model: | C57BL/6J mice[1]. | | Dosage: | 100 mg/kg. | | Administration: | I.G. (gavage) once daily for 7 days. | | Result: | Significantly decreased the plasma SM levels compared with vehicle group. |
| Animal Model: | ApoE KO mice (eight-week-old)[1]. | | Dosage: | 12.5 or 40 mg/kg. | | Administration: | I.G. (gavage) once daily. | | Result: | The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group. |
| [References]
[1]. Li Y, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882. |
|
|